Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK001 in atopic disease
NCT02563938Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic disease comparing AK001 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events at 86 days and Dose Limiting Toxicities at 86 days. Started Sep 2015; status: completed.
02
Drugs
AK001
03
Conditions
atopic disease
Beyond the preview
Go deeper on NCT02563938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02563938.